Neutrophil membrane biomimetic delivery system (Ptdser‐NM‐Lipo/Fer‐1) designed for targeting atherosclerosis therapy

Abstract Atherosclerosis is a progressive inflammatory disease characterised by excessive lipid accumulation and inflammatory cell infiltration and is the basis of most cardiovascular diseases and peripheral arterial diseases. Therefore, an effectively targeted delivery system is urgently needed to deliver ferroptosis‐specific inhibitors to the site of arterial plaque and the inflammatory microenvironment. Inspired by the fact that neutrophils can be recruited to arterial plaques under the action of adhesion molecules and chemokines, the authors developed a neutrophil membrane hybrid liposome nano‐mimetic system (Ptdser‐NM‐Lipo/Fer‐1) that delivers Ferrostatin‐1 (Fer‐1) to the atherosclerotic plaque effectively, which is composed of Fer‐1‐loaded Ptdser‐modified liposomes core and neutrophils shell. Fer‐1 was released at the AS plaque site to remove reactive oxygen species (ROS) and improve the inflammatory microenvironment. In vitro ROS clearance experiments have shown that 50 μmol/ml Fer‐1 can significantly remove ROS produced by H 2 O 2 ‐induced MOVAS cells and Ptdser‐NM‐Lipo/Fer‐1 revealed a 3‐fold increase in the inhibition rate of ROS than free Fer‐1 in induced‐RAW264.7, demonstrating its superior ROS‐cleaning effect. Based on the interaction of adhesion molecules, such as vascular cell adhesion molecule 1, ICAM‐1, P‐selectin, E‐selectin, and chemokines released in the inflamed site, the aorta in NM‐Lipo‐treated mice displayed 1.3‐fold greater radiant efficiency than platelet membrane‐Lipo‐treated mice. Meanwhile, due to the modification of the Ptdser, the aorta in Ptdser‐NM‐Lipo/Fer‐1‐treated mice exhibited the highest fluorescence intensity, demonstrating its excellent targeting ability for atherosclerosis. Therefore, we present a specific formulation for the treatment of atherosclerosis with the potential for novel therapeutic uses.